Contents

SECTION 1: FUNDAMENTALS AND PRELIMINARY CONSIDERATIONS IN OCULAR THERAPEUTICS

1. Ocular Defense System 3
Ashok Garg (India)

• Physical Protection 3 • Physiological Protection 5

2. Tear Film Physiology 9
Ashok Garg (India)

• Tear Film Formation Dynamics 14 • Normal Tear Drainage 15 • Tear Composition 16 • Physical Properties of Tears 16 • Chemical Composition of Tear Fluid 18 • Applied Physiology 29 • Hyposecretion of Tears 30 • Hypersecretion of Tears 33

3. Aqueous Humor Dynamics 38
Ashok Garg (India)

• Blood-Aqueous Barrier 38 • Aqueous Humor Formation 42 • Aqueous Humor Formation Regulation (Control) 44 • Rate of Flow of Movements of Aqueous Humor 45 • Routes of Aqueous Outflow (Escape) 45 • Aqueous Humor Composition 48 • Functions of Aqueous Humor 54

4. Routes of Administration and Drug Delivery Systems in Ophthalmology 55
Ashok Garg (India)

• Local Application 55 • Systemic Administration 61

5. Microorganisms and Ocular Diseases 67
Ashok Garg (India)

• Bacteria 67 • Fungi 68 • Viruses 69 • Parasites 69 • Common Microbiological Stains Used in Ophthalmology 69 • Common Ophthalmic Culture Media and Usage 70 • Normal Microbial Flora of the Eye 70

6. Unique Ocular Drug Delivery Systems 73
Xiadong Zheng (Japan), Marg E Marquart, Ashim K Mitra, James M Hill (USA)

• Unique Ocular Drug Delivery Systems 75 • Other Ocular Drug Delivery Systems 86 • Conclusion and New Perspectives 89

7. Antibacterial Therapy **97**
NR Biswas, GK Das, Harivenkatesh N, Ashok Garg (India)

• Routes of Antimicrobial Administration in Ophthalmic Practice 97 • Selection of Antimicrobial Agents 98 • Indications for Antimicrobial Therapy 99 • Mechanisms of Resistance to Antibiotics 100 • Steps to be taken to Avoid Antimicrobial Resistance 100 • Antimicrobial Combination Therapy 100 • Microbes Causing Ocular Infections 101 • Classification of Antibacterial Drugs (According to Mechanism of Action) 102 • Drugs that Inhibit Bacterial Cell Wall Synthesis 103 • Beta-Lactam Antibiotics 104 • Glycopeptide Antibiotics 113 • Fosfomycin 115 • Bacitracin 115 • Drugs Attacking Bacterial Cell Membrane 116 • Drugs that Inhibit Bacterial Protein Synthesis 116 • Individual Drugs 120 • Spectinomycin 123 • Tetracyclines 123 • Glycylcycline—Tigecycline 126 • Chloramphenicol 127 • Macrolides 128 • Individual Drugs 131 • Ketolides—Telithromycin 133 • Oxazolidinones—Linezolid 134 • Lincosamides—Clindamycin 135 • Streptogramins—Quinupristin/Dalfopristin 136 • Retapamulin 136 • Fusidic Acid 136 • Drugs Attacking Bacterial DNA 136 • Nitroimidazoles 143 • Drugs Affecting Bacterial Intermediate Metabolism 145 • Cotrimoxazole (Trimethoprim-Sulfamethoxazole) 146 • Mupirocin 147 • Antimicrobial Peptides 147 • Use of Antibiotics in Irrigating Solutions for Intraocular Surgery 149 • Reasons for Failure in Ocular Antibiotic Treatment 152

8. Anti-inflammatory Therapy **155**
NR Biswas, AK Dubey, Harivenkatesh N, Ashok Garg (India)

• Corticosteroids 155 • Nonsteroidal Anti-inflammatory Drugs 169 • Phenylalkanoic Acids 176 • Indoles 179 • Phenylacetic Acid 180 • Immunosuppressive Agents in Ophthalmology 184

9. Antiviral Therapy **193**
NR Biswas, Harivenkatesh N, KP Biswas, Ashok Garg (India)

• DNA Viruses 193 • RNA Viruses 193 • Mechanism of Viral Infection/Multiplication 194 • General Mechanisms of Action of Antiviral Agents 195 • Classification of Antiviral Drugs 196 • Antiherpes Agents 198 • Drugs Active Against

Cytomegalovirus 205 • Drugs Active Against Hepatitis Virus 211 • Drugs Used in HIV Infection 214 • Entry Inhibitor (Maraviroc) 221 • Fusion Inhibitor (Enfuvirtide) 221 • Integrase Inhibitor (Raltegravir) 222 • Clinical Use of Antiretroviral Therapy in Ophthalmology 222 • Drugs Active Against Influenza Virus 222

10. Antifungal Therapy **225**
NR Biswas, AK Dubey, Harivenkatesh N, Ashok Garg (India)

• Fungi Causing Ocular Infections 225 • Antifungal Drugs 226 • Polyenes 227 • Antimetabolite (Fluorinated Pyrimidine) 231 • Azole Derivatives 232 • Allylamines 239 • Echinocandins 241 • Silver Compounds 243

11. Antiglaucoma Therapy **245**
Ahmad K Khalil (Egypt)

• Aqueous Solutions 248 • Suspensions 248 • Ointments 248 • Gels 249 • Ocular Inserts 249 • Drug Compliance 249 • Prostaglandins (Hypotensive Lipids; HLS) 254 • Carbonic Anhydrase Inhibitors 258 • A2-Adrenergic Agonists 262 • Cholinergic Drugs 263

12. Antiallergy Therapy **280**
NR Biswas, GK Das, Harivenkatesh N, Ashok Garg (India)

• Type 1 Hypersensitivity Reactions 280 • Antiallergy Medication 281 • Topical Mast Cell Inhibitors 283 • Antihistamines 288 • Oral Antihistamines 293 • NSAIDs (Antiprostaglandin Therapy) 295 • Topical Steroids 295 • Topical Immunosuppressors 296 • Recent Advances in Immunosuppressive Therapy 296

13. Local Anesthetic Agents **299**
Ashok Garg (India)

• Local Anesthetics (Injectables) 299 • Esters 301 • Amides 303 • Local Anesthetics (Topical) 307 • Synopsis of Ophthalmic Uses of Local Anesthetics 313

14. Ophthalmic Viscosurgical Devices and Other Ocular Surgical Adjuncts **315**
Ashok Garg (India)

• Viscoelastic Substances 315 • Criteria for Selection of Viscoelastic Material 315 • Roles of Viscoelastic Substances 316 • Indications for Viscoelastic Substances 316 • Commercially Available Viscoelastic Substances 317 • Future

Viscoelastics 326 • Irrigating Solutions 326 • Surgical Enzymes 328 • Surgical Adjuncts 330 • Chelating Agents, Collagenase Inhibitors and Mucolytics 335 • Caustic Preparations in Ophthalmology 336 • Cyanoacrylate Tissue Adhesives in Ophthalmology 337

15. Mydriatics and Cycloplegics **340**
Ashok Garg (India)

• Mydriatic Adrenergic Agents (Sympathomimetic Agents) 340 • Cholinergic Antagonist as Mydriatic Agents 343 • Cycloplegic Mydriatics 343 • Mydriatic Combinations 348

16. Ophthalmic Dyes **351**
Ashok Garg (India)

• Fluorescein Sodium 351 • Fluorexon 356 • Rose Bengal 357 • Lissamine Green 358 • Indocyanine Green 358 • Trypan Blue 360 • Verteporfin (Visudyne) 362

17. Ocular Lubricants and Artificial Tear Solutions **369**
Ashok Garg (India)

• Artificial Tear Solutions 370 • Polyvinyl Alcohol Base Solutions 372 • Longer Lasting Mucoadhesive or Increased Viscosity Agents 373 • Polyvinyl Pyrrolidone Polymer Base Tear Solution 373 • Ointments 374 • Ocular Inserts (Solid Devices) 375 • Soft Contact Lens Therapy 376 • Punctal Plugs 376 • Collagen Implants 376 • Miscellaneous Preparations 377 • Recent Advances in New Polymers for Dry Eye Syndrome 377

18. Topical Immune Therapy **380**
Ashok Garg (India)

• Ocular Defense System and Immunity 380 • Indications for Topical Immune Therapy 383 • Dosage 384 • Contraindication 385 • Adverse Reactions 385

19. Topical Hyperosmotic Agents **387**
Ashok Garg (India)

• Major Causes of Corneal Edema 387 • Various Topical Hyperosmotic Agents Used in Ophthalmology 388

20. Antiretroviral Drug Therapy of Ocular Infections in AIDS **391**
Ashok Garg (India)

• HIV-Related Retinopathy 392 • Opportunistic Infections of the Eye 393 • Nonopportunistic

Infections 394 • Tumor Involvement 396
• Neuro-Ophthalmological Manifestations 397
• Cutaneous Hypersensitivity Reactions 397 • HIV in Ocular Structures 397 • Ocular Manifestations of HIV Infections in Children 397 • Antiretroviral Therapy of Ocular Infections in AIDS Patients 398
• Cytomegalovirus Infection 399
• Breakthrough Retinitis 404 • *Toxoplasma* Infection 405 • Herpes Zoster Ophthalmicus 405
• *Mycobacterium tuberculosis* 406 • *Mycobacterium avium* Intracellulare 406 • Ocular Syphilis 407
• Acute Retinal Necrosis 407 • *Pneumocystis carinii* Choroiditis 407 • Recent Advances in Antiretroviral Drug Therapy 407

21. Sterilization, Disinfection and Antiseptics in Ophthalmology **410**
Ashok Garg (India)

• Physical Methods 410 • Chemical Methods 418
• Soaking in Liquid Chemicals 419 • AIDS and Disinfection in Relation to Ophthalmology 426

22. Miscellaneous Drugs in Ophthalmology **430**
Ashok Garg (India)

• Lid Scrubs 430 • Astringent Ophthalmic Solution 431 • Ophthalmic Diagnostic Tear Test Strips 431 • Hamameli's Ophthalmic Solution 433
• Boric Acid 433 • Inactive Ingredients in Ophthalmic Products 433 • Viscosurgical Devices 436

23. Ocular Drug Toxicity: Complications **438**
Ashok Garg (India)

• Complications of Topical Antimicrobial Agents 440
• Complications of Steroids 443 • Systemic Adverse Reactions of Glaucoma Medications 452
• Complications of Topical Ocular Anesthetic Agents 457 • Toxicity of Surgical Solutions 460
• Complications of Contact Lens Solutions 465
• Complications of Intravenous Fluorescein 466
• Classification of Adverse Reactions 467 • Drug-induced Ocular Cicatrization 469 • Systemic Drugs Causing Ocular Toxicity 472

24. Topical and Systemic Ophthalmic Drugs with Common Dosages **492**
Ashok Garg (India)

• Antibiotic Therapy 492 • Topical Anti-inflammatory Therapy 494 • Antiviral Therapy 496
• Antifungal Therapy 498 • Antiglaucoma Therapy 499
• Antiallergy Therapy 502 • Local Anesthetic

Agents 504 • Mydriatics and Cycloplegics 505 • Artificial Tears and Lubricants 506 • Ophthalmic Viscosurgical Devices 508 • Irrigating Solutions 508 • Surgical Enzymes 509 • Surgical Adjuncts 509 • Topical Immune Therapy 510 • Topical Hyperosmotic Agent 510 • Anticataract Therapy 511 • Medical Therapy for Armd (Age-related Macular Degeneration) 512 • Medical Therapy for Diabetic Retinopathy 512 • Ophthalmic Dyes 512 • Contact Lens Care Products 514 • Recent Multipurpose Soft Lens Care Systems 515 • Antiretroviral Drugs in Ophthalmic Infections 516 • Ocular Therapeutics in Refractive Surgery 520

25. Ocular Manifestations of Systemic Diseases **523**
Ashok Garg (India)

• Various Systemic Diseases 523

26. Quick Look Tabulated Ocular Therapeutics Information **541**
Ashok Garg (India)

• Antibacterials 541 • Combination Antibiotics 542 • Anti-inflammatory Drugs 543 • Topical Steroid-antibiotic Combinations 544 • Antiviral Therapy 545 • Antifungal Therapy 546 • Anti-allergy Therapy 547 • Antiglaucoma Therapy 548 • Local Anesthetic Agents 551 • Local Anesthetic Combinations 552 • Mydriatics and Cycloplegics 552 • Ophthalmic Viscosurgical Devices (OVD) and Surgical Adjuncts 552 • Ophthalmic Dyes 555 • Lubricants and Artificial Tear Solutions 556 • Topical Immune Therapy 559 • Topical Hyperosmotic Agents 559 • Contact Lens Care Products 559 • Rewetting Solutions (Soft Lenses) 566 • Nonsurgical Adjuncts 566

SECTION 2: APPLIED OCULAR THERAPEUTICS IN OPHTHALMIC SURGERY

27. Comprehensive Review of Topical Ophthalmic Antibacterial Agents: Their Mechanisms of Action and Adverse Effects Including Long-Standing Drugs and the Most Recent Preparations **573**
Renée Solomon, Eric Donnenfeld (USA)

• Bacterial Conjunctivitis 573 • Bacterial Keratitis 574 • Properties of Topical Ophthalmic Antibacterial Agents 575 • Extemporaneously Compounded Fortified Antibiotics 582 • Aminoglycosides 582 • Bacitracin 584 • Beta-Lactam Antibiotics 585 • Chloramphenicol 587 • Macrolides 588

• Erythromycin 588 • Azithromycin 589
• Polymyxin and Combination Products 591
• Sulfacetamide 592 • Tetracyclines 593
• Vancomycin 594 • Selecting the Optimal Ophthalmic Antibiotic 595 • Clinical Judgment in Choosing an Ophthalmic Antibiotic 595
• Bacterial Conjunctivitis 596 • Bacterial Keratitis 596
• Norfloxacin 0.3 Percent Solution 597

28. Preoperative and Postoperative Antibiotic Prophylaxis in Cataract Surgery **606**
NR Biswas, Srujana Mohanty, GK Das, Madhurjya Gogoi (India)

• Antibiotic Prophylaxis 607 • Chloramphenicol 609
• Topical Fluoroquinolones 610 • Lomefloxacin 610
• Fourth Generation Fluoroquinolones 611
• Intracameral Antibiotics 612

29. Management of Iatrogenic Inflammation of the Eye **615**
NR Biswas, GK Das, Vinay Gupta (India)

• Topical Application 615 • Use of Nonsteroidal Anti-inflammatory Drugs in Inflammation 619

30. Management of Postrefractive Keratitis **625**
Eric D Donnenfeld (USA)

31. Ocular Pharmacotherapeutics in Corneal Refractive Surgery **631**
Ashok Garg (India)

• Preprocedure Therapeutic Medications 631
• Postprocedure Therapeutic Medications 632

32. Antioxidants and Their Role in Ophthalmology **635**
CS Dhull, Sumit Sachdeva, Manisha Rathi, Ashuma Sachdeva (India)

• Classification of Antioxidants 637

33. Tetracyclins for Ocular Surface Diseases **647**
Robert Latkany (USA)

34. Clinical Applications of Antimycotic Agents in the Eye **651**
Niranjan Nayak (India)

• Keratomycosis 651 • Orbital Cellulitis 655
• Dacryocystitis 656 • Endophthalmitis 656

35. Recommended Antibiotic Dosages for Various Clinical Conditions of the Eye **662**
Ashok Garg (India)

36. Endophthalmitis Prevention Strategies **670**
John D Sheppard (USA)
• New Concepts in Endophthalmitis Treatment 670 • Existing Literature 671 • Practical Clinical Practice 671 • Microbial Antibiotic Resistance 672

37. Management of Myopic Choroidal Neovascularization **674**
Jose M Ruiz Moreno, Javier A Montero (Spain)
• Photodynamic Therapy 674
• Intravitreal Anti-VEGF Drug Injection 676

38. Treatment of Central Serous Choroidopathy **685**
Pedro Amat Peral, Francisco Lugo, Jose M Ruiz Moreno (Spain)
• Differential Diagnosis 689 • Treatment 689
• Pathogenesis 693 • Case Report 694

39. Treatment of Retinal Angiomatous Proliferation **702**
Javier A Montero, Jose M Ruiz-Moreno, Jorge Ruiz-Medrano (Spain)
• Natural History 704

40. Conjunctival Allergen Challenge for Evaluating Anti-inflammatory Therapy **716**
Mitchell Friedlaender, Daphne Bresheaus (USA)
• Abstract 716 • Methods 717 • Results 719

41. Steroid Therapy for Allergic Ocular Disease **725**
John D Sheppard (USA)
• New Concepts in Topical Steroid Therapy 725
• The Nature of Allergic Disease 727 • Combined Surface Diseases Present Diagnostic Challenges 728
• Innovative Strategies for Ocular Surface Diseases 730
• Blepharitis Exacerbates Dry Eyes and Allergy 735
• Steroids for Contact Lens Wearers and Refractive Surgery Patients 740

42. Optimizing Visual Outcomes with NSAIDs Therapy in Cataract and Refractive Surgeries **744**
Eric D Donnenfeld, Henry D Perry (USA)
• Rationale for Treating Ocular Inflammation 745
• Pharmacologic Therapy for Ocular Inflammation 746

43. Immunosuppressive Drugs in Ophthalmology **756**
Ashok Garg (India)
• Selection of Patients 756 • Alkylating Agents 756
• Antimetabolites 757 • Antibiotic Cyclosporin A 758

• Ocular Drug Toxicity of Immunosuppressive Agents used in Ophthalmic Conditions 759 • Recent Advances in Immunosuppressive Therapy 759

44. Management of Cystoid Macular Edema **762**
Arturo Perez Arteaga, Rene-Cano Hidalgo (Mexico)

• Definition 762 • Etiology 762 • Histopathology 765 • Clinical Findings 765 • Paraclinical Approach 766 • Treatment 767

45. Blepharitis **775**
Mitchell Friedlaender (USA)

• Classification 775 • Genetics 775 • Infection 776 • Allergy 777 • Corneal Manifestations 778 • Chemistry 779 • Treatment 779

46. Trypan Blue in the Management of Mature Cataract **782**
Amar Agarwal, Athiya Agarwal, Sunita Agarwal (India)

• Rhexis in Mature Cataracts 782 • Trypan Blue 782 • Technique 783 • Adverse Effects 790 • Sterilization 790 • Indocyanine Green Dye 790

47. Trypan Blue Assisted Epiretinal Membrane Removal **791**
Amar Agarwal, Athiya Agarwal, Sunita Agarwal, Saurabh Choudhry, Reena M Choudhry (India)

• Patients and Technique 791 • Results 793

48. Perfluorocarbon Liquids in Vitreoretinal Surgery **795**
Amar Agarwal (India)

• Types 795 • Physical Properties 795 • Indications 802 • Miscellaneous 807 • Other Medical Applications 808 • Complications 808

49. Use of Tissue Adhesives in Ophthalmology **810**
Prateek Gujar, Purendra Bhasin, Priyamvada Bhasin (India)

• Cyanoacrylate Tissue Adhesives 811 • Human Fibrin Glues 812 • Recent Advances in Tissue Adhesives in Ophthalmology 813

50. Photodynamic Therapy (Verteporfin) in Age-related Macular Degeneration **816**
S Natarajan, Anand Bagmar (India)

• Technique 817 • Preparation of the Patient for PDT 818 • Calculation of the Treatment Spot Size Required Covering the CNV 819

51. Indocyanine Green Angiography **822**
S Natarajan, Anand Bagmar (India)

• Advantages of ICG 822 • History 822 • Pharmacology 823 • Toxicity 823 • Technique 823 • Various Phases of ICG Angiography 823 • ICG in Age Related Macular Degeneration 824

52. Management of Dry Eye—Current Trends and Recent Advances **833**
Anthony Vipin Das, Virender Sangwan (India)

• Medical Management 833 • Ongoing Clinical Trials 841

53. Management of Endophthalmitis: Antibiotic Schedule and Dosages **847**
Pei-Chang Wu, Hsi-Kung Kuo (Taiwan)

• Acute Postoperative Endophthalmitis 847

54. Surgical Techniques of Glued IOL **860**
Ashvin Agarwal, Amar Agarwal (India)

• Scleral Fixated IOL 860 • Fibrin Glue 860 • Surgical Technique 860 • Discussion 861

55. Intraocular Gases **870**
S Natarajan, Pandurang Kulkarni, Navendu Rai, Shachi Desai, Vinay Prasad, Rishi Bhardwaj, Anoop Sivaraman (India)

• Physical Properties of Gases 870 • Intraocular Gas Geometry 871 • Intraocular Gas Kinetics 871 • Effect of Anesthetic Gases and Atmospheric Depressurization 873 • Clinical Considerations 873 • Choice of Gas 873 • Nonexpansile Concentration 876 • Techniques of Fluid-Air Exchange and Intraocular Gas Injection 876 • Clinical Uses 878 • Postoperative Management 879 • Toxicity and Complications 880

56. Pharmacology of Anti-VEGF Therapy **883**
T Mark Johnson (USA)

• Vascular Endothelial Growth Factor and Angiogenesis 883 • Administration of Anti-VEGF Therapy 885 • Side Effects of Anti-VEGF Therapy 885

SECTION 3: RECENT ADVANCES IN OCULAR THERAPEUTICS

57. Toxic Anterior Segment Syndrome **891**
Simon P Holland, Douglas W Morck, Richard Mathias, Tracy L Lee, Gina Chavez, Yumi G Ohashi (Canada)

58. Anesthesia Trends in Ophthalmology **899**
Arbisser Lisa

• History 899 • Perioperative Workup 899 • Trends in Topical Anesthesia 900 • Trends in Regional Anesthesia 900 • Author's Technique 901

59. Azithromycin in Ophthalmology: A New Therapy **905**
Eric Donnenfeld, Mitchell Friedlaender (USA)

• Topical Azithromycin Eyedrop (Azasite) 905 • Chemical Structures of Azithromycin and Erythromycin 906 • Modeled Bioavailability of Azithromycin from Azasite 907

60. Use of Beta-adrenergic Blockers in Ocular Vascular Diseases **911**
Javier A Montero, Jose M Ruiz-Moreno, Eugenia Sanchis-Merino (Spain)

61. Clinical Applications of Anti-inflammatory and Anti-protease Effects of Tetracyclines in Ocular Surface Disease **924**
Stephen C Pflugfelder, Cintia S De Paiva, De-Quan Li (USA)

62. Optimized NSAIDs and Antibacterial Regimen is Key to Ocular Surgical Prophylaxis **935**
Ashok Garg (India), Ian Bell (USA)

• Postoperative Schedule for Cataract Patients 936 • Measuring Potency 937 • Penetration Tracking 938 • Safety Evaluation 938

63. Ophthalmic Medications in Pediatric Age Group **940**
Rami Pai, Kirit Mody (India)

• Precautions 940 • Mydriatic Agents 941 • Glaucoma Medications 944 • Anti-inflammatory Drugs 950 • Anti-allergy Medications 953 • Antibiotics 956 • Sulfonamides 960 • Aminoglycosides 961 • Macrolides 962 • Tetracyclines 962 • Chloramphenicol 963 • Fluoroquinolones 964 • Antivirals 964 • Antifungals 967

64. Management of Uveitis in Children **971**
Gagandeep Singh Brar, SPS Grewal (India)

• Juvenile Idiopathic Arthritis Associated Uveitis 972 • Fuchs Heterochromic Uveitis 974 • Intermediate Uveitis 975 • Behçet's Disease 976 • Toxoplasmosis 977 • Toxocariasis 979

65. Management of Anticoagulation Therapy in Elective Ophthalmic Procedures **982**
Purendra Bhasin, Prateek Gujar, Priyamvada Bhasin, Prachi Tomar (India)

• Identifying the Patients at Risk 982 • Risk of Bleeding Complications 983 • Modifying Antithrombotic Therapy During Ophthalmic Surgery 984 • Intraoperative Considerations to Reduce Bleeding in Patients Using Anticoagulation Therapy 985

66. Ocular Pharmacology of Intravitreal Dexamethasone Sustained Release Implant **988**
Priyamvada Bhasin, Amit Basia, Purendra Bhasin (India)

• Mechanism of Action 988 • Chemical Formula 989
• Technique 990 • Pharmacokinetics 990
• Indications 991 • Contraindications 994
• Adverse Effects 994

67. Nanotechnology in Ophthalmology **996**
NR Biswas, Harivenkatesh N, KP Biswas, Alok K Ravi, Madhurjya Gogoi (India)

• Medicine and Nanotechnology 996
• Nanotechnology in Ophthalmology 1000
• Ocular Distribution of Nanoparticles 1004
• Future of Nanotechnology 1005

68. Photochemical Therapy for Corneal Infections **1007**
Ammar M Al Mahmood, Ashley Behrens (Saudi Arabia)

• Antimicrobial Effects of PCTCI 1007
• Microbial Keratitis Following CXL 1012
• Microbial Keratitis Following Other PDT Approaches 1014 • Antimicrobial Effect of Other PDT Approaches 1014

69. Recent and Future Drugs in Ophthalmology **1020**
Roberto Bellucci, Carlo Bellucci (Italy)

• Recent and Emerging Drugs 1020
• New Drug Delivery in Ophthalmology 1023
• Biological Transporters and Prodrugs 1024
• Colloidal Carriers and Nanoparticles 1025

Index *1035*